The best hair loss treatment depends on the underlying cause, and choosing the right approach begins with an accurate diagnosis. Hair loss — medically termed alopecia — affects millions of people across the UK, from androgenetic alopecia and alopecia areata to telogen effluvium triggered by stress or nutritional deficiency. With a range of NHS-supported, prescription, and private options available, navigating the evidence can feel overwhelming. This guide covers clinically recognised treatments, including minoxidil and finasteride, alongside safety considerations and guidance on when to seek medical advice — helping you make an informed decision with your GP or dermatologist.

Common Causes of Hair Loss in the UK

Androgenetic alopecia is the most prevalent cause, but telogen effluvium, alopecia areata, thyroid disorders, and iron deficiency are also common; identifying the cause is essential before starting treatment.

Hair loss, known medically as alopecia, is a common concern affecting millions of people across the UK. Understanding the underlying cause is the essential first step before considering any treatment, as different conditions respond to very different approaches.

Not sure if this is normal? Chat with one of our pharmacists →

The most prevalent form is androgenetic alopecia (male- or female-pattern hair loss), a hereditary condition driven by sensitivity to dihydrotestosterone (DHT), a derivative of testosterone. It affects approximately 50% of men by the age of 50 and a significant proportion of women, particularly after the menopause.

Other common causes include:

• Alopecia areata – an autoimmune condition causing patchy hair loss, affecting around 2% of the UK population at some point in their lives

• Telogen effluvium – diffuse shedding triggered by physical or emotional stress, illness, nutritional deficiencies, or hormonal changes; postpartum telogen effluvium is particularly common and typically resolves spontaneously over several months once the trigger is addressed

• Thyroid disorders – both hypothyroidism and hyperthyroidism can cause diffuse thinning

• Iron deficiency anaemia – a particularly common cause in women of reproductive age

• Scalp conditions – such as tinea capitis (ringworm of the scalp, predominantly affecting children) or seborrhoeic dermatitis

• Traction alopecia – hair loss caused by persistent tension from tight hairstyles

• Trichotillomania – compulsive hair pulling, which may require psychological support

• Medication-related hair loss – certain drugs, including anticoagulants, retinoids, and some antidepressants, are associated with hair thinning

Red flags requiring prompt medical assessment include: sudden or rapidly progressive hair loss; patchy loss accompanied by scalp redness, scaling, pustules, pain, or burning (which may suggest a scarring alopecia such as lichen planopilaris or frontal fibrosing alopecia); suspected tinea capitis in a child; loss of eyebrows or eyelashes; or hair loss accompanied by systemic symptoms such as fatigue, weight change, or skin changes. Suspected scarring alopecia and tinea capitis warrant prompt referral to a dermatologist, as early treatment can prevent permanent follicle damage.

A GP assessment is recommended before starting any treatment. Routine initial blood tests typically include TSH, full blood count, and serum ferritin. Testing for serum androgens is not routinely indicated unless there are clinical features suggesting hyperandrogenism (such as hirsutism, irregular periods, or acne). Further investigations should be guided by the history and examination findings. Identifying and addressing a reversible cause — such as correcting an iron deficiency — may resolve hair loss without the need for specific hair loss therapies.

Sources: NHS (Hair loss overview); NICE CKS (Alopecia areata); Primary Care Dermatology Society (PCDS) guidance on hair loss; British Association of Dermatologists (BAD) patient information.

NHS-Recommended Hair Loss Treatments Available

The NHS supports topical minoxidil and finasteride for androgenetic alopecia, though most treatments are purchased privately; corticosteroid injections and DPCP are offered for alopecia areata via dermatology.

The NHS acknowledges that hair loss can have a significant psychological impact and offers guidance on evidence-based options. It is important to note that many treatments are not routinely funded on the NHS and may need to be accessed privately. The GP is the first point of contact within the NHS; referral to NHS dermatology is via the GP and is subject to local commissioning criteria.

For androgenetic alopecia, topical minoxidil (available over the counter) and oral finasteride (for men, prescription-only) are the treatments with the strongest evidence base. These are discussed in detail in the following section. Both are typically purchased privately in the UK rather than prescribed on the NHS.

For alopecia areata, the NHS may offer:

• Corticosteroid injections (intralesional triamcinolone) into affected areas — a first-line option for patchy disease

• Topical corticosteroids

• Referral to a dermatologist for contact immunotherapy with diphencyprone (DPCP) in more extensive or refractory cases; this treatment is specialist-delivered and not universally available across all NHS centres

For telogen effluvium, the NHS approach focuses on identifying and treating the underlying trigger rather than prescribing hair-specific treatments. This may involve:

• Dietary advice and supplementation where deficiencies are confirmed

• Management of underlying thyroid disease or anaemia

• Psychological support where stress is a contributing factor

Telogen effluvium often resolves over several months once the precipitating cause is addressed, and patients can be reassured of this.

NICE does not currently have a dedicated guideline specifically for androgenetic alopecia, but NHS guidance aligns with established dermatological practice. Patients experiencing significant distress related to hair loss may be referred for psychological support or counselling. Wigs are available on the NHS for some patients, including those undergoing chemotherapy, subject to eligibility criteria that vary by region.

Sources: NHS (Hair loss and treatment access); BAD guidelines; PCDS guidance on alopecia areata.

Prescription Options: Finasteride, Minoxidil and Beyond

Finasteride 1 mg (prescription-only) and topical minoxidil (over the counter) are the two agents with the strongest evidence for androgenetic alopecia; JAK inhibitors baricitinib and ritlecitinib are MHRA-authorised for severe alopecia areata.

When it comes to evidence-based pharmacological treatments, two agents dominate clinical practice in the UK: minoxidil and finasteride. Both are regulated by the MHRA.

Minoxidil is available over the counter in topical form (2% and 5% solutions or foam) for both men and women. Its precise mechanism is not fully understood, but it is thought to prolong the anagen (growth) phase of the hair cycle and increase blood flow to hair follicles, resulting in increased follicle size. Results typically take three to six months to become apparent, and treatment must be continued indefinitely to maintain benefit.

An oral low-dose minoxidil formulation is increasingly used for hair loss under dermatologist supervision; however, it is important to note that oral minoxidil is not licensed for hair loss in the UK and its use in this context is off-label. It requires clinician oversight, blood pressure monitoring, and is not recommended during pregnancy or breastfeeding, or in patients with significant cardiovascular disease.

Finasteride 1 mg daily (brand name Propecia) is a 5-alpha reductase inhibitor that reduces DHT levels in the scalp, slowing hair loss and promoting regrowth in men with androgenetic alopecia. It is a prescription-only medicine (POM) in the UK and is not licensed for use in women, particularly those of childbearing potential, due to the risk of feminisation of a male foetus. The licensed dose for androgenetic alopecia in men is 1 mg; the 5 mg formulation (licensed for benign prostatic hyperplasia) is not recommended for androgenetic alopecia and carries a higher risk of adverse effects.

Experiencing these side effects? Our pharmacists can help you navigate them →

Dutasteride, another 5-alpha reductase inhibitor with a broader mechanism of action, is used off-label for hair loss in some specialist settings. It is not licensed for androgenetic alopecia in the UK. Like finasteride, it carries risks of sexual side effects and is teratogenic; women of childbearing potential must use effective contraception if dutasteride is prescribed, and specialist oversight is required.

For alopecia areata, newer treatments including JAK inhibitors represent a significant advance for patients with severe or refractory disease. Baricitinib (Olumiant) and ritlecitinib (Litfulo) have received MHRA marketing authorisations for severe alopecia areata in adults (and ritlecitinib for adolescents aged 12 and over). Access within the NHS is subject to NICE technology appraisal outcomes and local commissioning decisions; patients should discuss eligibility with a specialist dermatologist. These agents are not suitable for all patients and carry their own safety considerations.

Sources: EMC/SmPC: Propecia (finasteride 1 mg); EMC/SmPC: Regaine (minoxidil topical); MHRA Drug Safety Update (finasteride); BNF monographs (finasteride, minoxidil, dutasteride); MHRA/EMA product information (baricitinib; ritlecitinib).

How to Choose the Right Treatment for Your Hair Loss

Treatment choice depends on hair loss type, sex, age, and medical history; men with androgenetic alopecia benefit most from combined minoxidil and finasteride, while topical minoxidil is first-line for women.

Selecting the most appropriate treatment depends on several factors, including the type and pattern of hair loss, its severity, your sex, age, medical history, and personal preferences. There is no single 'best hair loss treatment' that applies universally — a tailored approach is always recommended.

For men with androgenetic alopecia, the combination of topical minoxidil and oral finasteride (1 mg) is generally considered the most effective evidence-based strategy, with studies suggesting superior outcomes when used together compared with either agent alone.

For women, topical minoxidil (2% or 5%) remains the first-line option. In premenopausal women with features of hyperandrogenism, off-label spironolactone may be considered under specialist guidance; this requires reliable contraception (as it may feminise a male foetus), and monitoring of renal function and potassium levels. In postmenopausal women, off-label finasteride or dutasteride may occasionally be considered by a specialist with appropriate counselling about the limited evidence base and potential risks. Oral contraceptives are not appropriate for postmenopausal women and are not a recommended treatment for female-pattern hair loss in this group.

Key considerations when choosing a treatment:

• Duration of commitment – most treatments require long-term, consistent use; stopping treatment typically results in reversal of any gains within months

• Cost – prescription treatments and private dermatology consultations involve out-of-pocket costs for most patients

• Lifestyle factors – topical treatments require daily application and may affect hair styling routines; avoiding tight hairstyles and managing scalp conditions such as seborrhoeic dermatitis can support scalp health

• Underlying cause – if hair loss is secondary to a medical condition, treating that condition should take priority

Non-pharmacological options may also be relevant for some patients. Hair transplantation (follicular unit extraction or transplantation) can be effective for suitable candidates with stable androgenetic alopecia and is performed privately in the UK. Low-level laser therapy (LLLT) devices are available but evidence of benefit remains modest. Cosmetic camouflage products (fibres, sprays, and scalp micropigmentation) can help manage the appearance of thinning hair.

Accessing care: The GP is the recommended first point of contact. NHS dermatology is accessed via GP referral. Private dermatology clinics can provide specialist assessment without a referral. Note that the title 'trichologist' is not a protected or statutorily regulated title in the UK; for diagnosis and prescribing, a medically qualified dermatologist or GP with a specialist interest is preferable. Be cautious of unregulated online clinics or products making exaggerated claims, and always ensure any prescribed medication comes from a registered UK pharmacy.

Sources: NICE CKS (Alopecia areata; Female pattern hair loss); PCDS guidance (androgenetic alopecia); BAD patient information leaflets.

Side Effects and Safety Considerations

Finasteride carries MHRA-flagged risks including mood changes, persistent sexual dysfunction, and teratogenicity; topical minoxidil is generally well tolerated but should not be used in pregnancy or breastfeeding.

All treatments carry a potential for side effects, and understanding these is essential for making an informed decision. The MHRA monitors the safety of licensed medicines in the UK and provides up-to-date guidance for both patients and prescribers.

Minoxidil (topical) is generally well tolerated. Reported side effects include:

• Scalp irritation, dryness, or flaking

• Unwanted facial hair growth (particularly in women using higher-strength formulations)

• Initial increased shedding in the first few weeks of use — this is a normal part of the hair cycle reset and usually resolves

• Topical minoxidil should not be used during pregnancy or breastfeeding, and should not be applied to broken or irritated skin

• Rarely, systemic effects such as fluid retention or palpitations are more commonly associated with oral minoxidil (off-label use); oral minoxidil requires blood pressure monitoring and clinician supervision, and is not recommended in pregnancy, breastfeeding, or significant cardiovascular disease

Finasteride carries more significant safety considerations. The MHRA has issued Drug Safety Updates noting that patients should be made aware of the following:

• Reduced libido, erectile dysfunction, or ejaculatory disorders — these may occur in a small proportion of men

• Mood changes, depression, and suicidal ideation — patients should be advised to stop finasteride and seek urgent medical attention if they experience psychological symptoms

• Persistent sexual dysfunction — there are reports of sexual and psychological side effects continuing after stopping the medication (sometimes referred to as post-finasteride syndrome); this is subject to ongoing regulatory review and patients should be counselled accordingly before starting treatment

• Possible effects on fertility — finasteride may reduce semen parameters in some men; this may improve on stopping the medication

• Breast changes — any breast tenderness, lumps, or nipple discharge should be reported to a doctor promptly

• Finasteride lowers PSA (prostate-specific antigen) levels by approximately 50%; patients should inform their clinician that they are taking finasteride if PSA testing is carried out, as this affects interpretation of results

Women who are pregnant or may become pregnant must not handle crushed or broken finasteride tablets due to the risk of foetal harm.

For any treatment, patients should:

• Report unexpected or persistent side effects to their GP or via the MHRA Yellow Card scheme (accessible at yellowcard.mhra.gov.uk)

• Not exceed recommended doses

• Seek prompt medical review if hair loss is sudden, patchy, or accompanied by other symptoms such as fatigue, weight changes, or skin changes, as these may indicate an underlying medical condition requiring investigation

Sources: EMC/SmPC: Propecia (finasteride 1 mg); EMC/SmPC: Regaine (minoxidil topical); MHRA Drug Safety Update: finasteride — psychiatric and sexual adverse reactions; BNF monographs (finasteride, minoxidil).

Frequently Asked Questions